GB9624038D0 - Organic compounds - Google Patents

Organic compounds

Info

Publication number
GB9624038D0
GB9624038D0 GBGB9624038.7A GB9624038A GB9624038D0 GB 9624038 D0 GB9624038 D0 GB 9624038D0 GB 9624038 A GB9624038 A GB 9624038A GB 9624038 D0 GB9624038 D0 GB 9624038D0
Authority
GB
United Kingdom
Prior art keywords
organic compounds
optionally substituted
chem
independently
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GBGB9624038.7A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sandoz AG
Original Assignee
Sandoz AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz AG filed Critical Sandoz AG
Priority to GBGB9624038.7A priority Critical patent/GB9624038D0/en
Publication of GB9624038D0 publication Critical patent/GB9624038D0/en
Priority to CA002270952A priority patent/CA2270952C/en
Priority to ES97951219T priority patent/ES2227726T3/es
Priority to DK02025422T priority patent/DK1312359T3/da
Priority to RU99112577/14A priority patent/RU2217136C2/ru
Priority to HU0000343A priority patent/HUP0000343A3/hu
Priority to PT02025422T priority patent/PT1312359E/pt
Priority to SI9730678T priority patent/SI0941082T1/xx
Priority to US09/308,098 priority patent/US6274629B1/en
Priority to NZ335629A priority patent/NZ335629A/en
Priority to PT97951219T priority patent/PT941082E/pt
Priority to DE69738033T priority patent/DE69738033T2/de
Priority to BR9713105-9A priority patent/BR9713105A/pt
Priority to JP52320098A priority patent/JP4004070B2/ja
Priority to EP97951219A priority patent/EP0941082B1/en
Priority to IDW990370A priority patent/ID21568A/id
Priority to ES02025422T priority patent/ES2289041T3/es
Priority to SI9730772T priority patent/SI1312359T1/sl
Priority to IL12982497A priority patent/IL129824A/xx
Priority to PCT/EP1997/006408 priority patent/WO1998022100A2/en
Priority to HK00101496.7A priority patent/HK1022639B/en
Priority to AU54831/98A priority patent/AU728420B2/en
Priority to EP02025422A priority patent/EP1312359B1/en
Priority to CNB971998582A priority patent/CN1146411C/zh
Priority to CZ991749A priority patent/CZ174999A3/cs
Priority to PL97333463A priority patent/PL190348B1/pl
Priority to AT97951219T priority patent/ATE275947T1/de
Priority to CNB2004100059961A priority patent/CN1293876C/zh
Priority to DE69730727T priority patent/DE69730727T2/de
Priority to SK659-99A priority patent/SK284806B6/sk
Priority to IL14709997A priority patent/IL147099A0/xx
Priority to AT02025422T priority patent/ATE369846T1/de
Priority to NO992259A priority patent/NO992259L/no
Priority to US09/898,143 priority patent/US6486209B2/en
Priority to US10/261,536 priority patent/US20030069315A1/en
Priority to JP2004152002A priority patent/JP2004256554A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/131—Amines acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Light Receiving Elements (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polyurethanes Or Polyureas (AREA)
  • Peptides Or Proteins (AREA)
GBGB9624038.7A 1996-11-19 1996-11-19 Organic compounds Pending GB9624038D0 (en)

Priority Applications (36)

Application Number Priority Date Filing Date Title
GBGB9624038.7A GB9624038D0 (en) 1996-11-19 1996-11-19 Organic compounds
AT02025422T ATE369846T1 (de) 1996-11-19 1997-11-17 Verwendung von 1,3-propanediol derivaten
ES02025422T ES2289041T3 (es) 1996-11-19 1997-11-17 Uso de compuestos de 1,3-propanodiol.
ES97951219T ES2227726T3 (es) 1996-11-19 1997-11-17 Nuevo uso de derivados de 1,3-propanodiol.
DK02025422T DK1312359T3 (da) 1996-11-19 1997-11-17 Anvendelse af 1,3-propandiolforbindelser
RU99112577/14A RU2217136C2 (ru) 1996-11-19 1997-11-17 Новое применение 1,3-пропандиольных производных
HU0000343A HUP0000343A3 (en) 1996-11-19 1997-11-17 Use for 1,3-propanediol derivatives to prevent rejection after organ transplantation
PT02025422T PT1312359E (pt) 1996-11-19 1997-11-17 Utilização de compostos 1, 3-propanodiol
SI9730678T SI0941082T1 (en) 1996-11-19 1997-11-17 New use for 1,3-propanediol derivatives
US09/308,098 US6274629B1 (en) 1996-11-19 1997-11-17 Use for 1,3-propanediol derivatives
NZ335629A NZ335629A (en) 1996-11-19 1997-11-17 Use of 1,3-propanediol derivatives for preventing or treating graft vessel disease
PT97951219T PT941082E (pt) 1996-11-19 1997-11-17 Nova utilizacao para derivados de 1,3-propanodiol
DE69738033T DE69738033T2 (de) 1996-11-19 1997-11-17 Verwendung von 1,3-propanediol derivaten
BR9713105-9A BR9713105A (pt) 1996-11-19 1997-11-17 Uso para os derivados de 1,3 - propanodiol
JP52320098A JP4004070B2 (ja) 1996-11-19 1997-11-17 １，３―プロパンジオール誘導体の新しい用途
EP97951219A EP0941082B1 (en) 1996-11-19 1997-11-17 New use for 1,3-propanediol derivatives
IDW990370A ID21568A (id) 1996-11-19 1997-11-17 Penggunaan baru untuk turunan 1,3-propanadiol
CA002270952A CA2270952C (en) 1996-11-19 1997-11-17 New use for 1,3-propanediol derivatives
IL12982497A IL129824A (en) 1996-11-19 1997-11-17 Pharmaceutical compositions comprising 2-amino-1,3-propanediol derivatives for preventing and/or treating chronic rejection in a recipient for organ or tissue allo- or xenotransplants
SI9730772T SI1312359T1 (sl) 1996-11-19 1997-11-17 Uporaba 1,3-propandiolnih spojin
SK659-99A SK284806B6 (sk) 1996-11-19 1997-11-17 Použitie derivátu 2-amino-1,3-propándiolu
HK00101496.7A HK1022639B (en) 1996-11-19 1997-11-17 New use for 1,3-propanediol derivatives
AU54831/98A AU728420B2 (en) 1996-11-19 1997-11-17 New use for 1,3-propanediol derivatives
EP02025422A EP1312359B1 (en) 1996-11-19 1997-11-17 Use for 1,3-propanediol compounds
CNB971998582A CN1146411C (zh) 1996-11-19 1997-11-17 1,3-丙二醇衍生物的新用途
CZ991749A CZ174999A3 (cs) 1996-11-19 1997-11-17 Nové použití derivátů 2-amino-1,3-propandiolu
PL97333463A PL190348B1 (pl) 1996-11-19 1997-11-17 Nowe zastosowania pochodnych 1,3-propanodiolu
AT97951219T ATE275947T1 (de) 1996-11-19 1997-11-17 Neue verwendung von 1,3-propanediol derivaten
CNB2004100059961A CN1293876C (zh) 1996-11-19 1997-11-17 1，3－丙二醇衍生物的新用途
DE69730727T DE69730727T2 (de) 1996-11-19 1997-11-17 Neue verwendung von 1,3-propanediol derivaten
PCT/EP1997/006408 WO1998022100A2 (en) 1996-11-19 1997-11-17 New use for 1,3-propanediol derivatives
IL14709997A IL147099A0 (en) 1996-11-19 1997-11-17 New use for 1,3-propanediol derivatives
NO992259A NO992259L (no) 1996-11-19 1999-05-10 Ny anvendelse for 1,3-propandiolderivater
US09/898,143 US6486209B2 (en) 1996-11-19 2001-07-03 Use for 1,3-propanediol derivatives
US10/261,536 US20030069315A1 (en) 1996-11-19 2002-09-30 New use for 1,3-propanediol derivatives
JP2004152002A JP2004256554A (ja) 1996-11-19 2004-05-21 １，３−プロパンジオール誘導体の新しい用途

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9624038.7A GB9624038D0 (en) 1996-11-19 1996-11-19 Organic compounds

Publications (1)

Publication Number Publication Date
GB9624038D0 true GB9624038D0 (en) 1997-01-08

Family

ID=10803173

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB9624038.7A Pending GB9624038D0 (en) 1996-11-19 1996-11-19 Organic compounds

Country Status (24)

Country Link
US (3) US6274629B1 (cg-RX-API-DMAC10.html)
EP (2) EP1312359B1 (cg-RX-API-DMAC10.html)
JP (2) JP4004070B2 (cg-RX-API-DMAC10.html)
CN (2) CN1146411C (cg-RX-API-DMAC10.html)
AT (2) ATE275947T1 (cg-RX-API-DMAC10.html)
AU (1) AU728420B2 (cg-RX-API-DMAC10.html)
BR (1) BR9713105A (cg-RX-API-DMAC10.html)
CA (1) CA2270952C (cg-RX-API-DMAC10.html)
CZ (1) CZ174999A3 (cg-RX-API-DMAC10.html)
DE (2) DE69730727T2 (cg-RX-API-DMAC10.html)
DK (1) DK1312359T3 (cg-RX-API-DMAC10.html)
ES (2) ES2227726T3 (cg-RX-API-DMAC10.html)
GB (1) GB9624038D0 (cg-RX-API-DMAC10.html)
HU (1) HUP0000343A3 (cg-RX-API-DMAC10.html)
ID (1) ID21568A (cg-RX-API-DMAC10.html)
IL (1) IL129824A (cg-RX-API-DMAC10.html)
NO (1) NO992259L (cg-RX-API-DMAC10.html)
NZ (1) NZ335629A (cg-RX-API-DMAC10.html)
PL (1) PL190348B1 (cg-RX-API-DMAC10.html)
PT (2) PT1312359E (cg-RX-API-DMAC10.html)
RU (1) RU2217136C2 (cg-RX-API-DMAC10.html)
SI (1) SI1312359T1 (cg-RX-API-DMAC10.html)
SK (1) SK284806B6 (cg-RX-API-DMAC10.html)
WO (1) WO1998022100A2 (cg-RX-API-DMAC10.html)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000027798A1 (en) 1998-11-11 2000-05-18 Novartis Ag Production of 2-amino-2-[2-(4-c2-20-alkyl-phenyl)ethyl]propane-1,3-diols
HUP0204069A3 (en) * 1999-12-16 2005-01-28 Teva Pharma Novel processes for making- and a new crystalline form of- leflunomide and pharmaceutical composition containing it
WO2002018395A1 (en) 2000-08-31 2002-03-07 Merck & Co., Inc. Phosphate derivatives as immunoregulatory agents
JP4318921B2 (ja) * 2001-02-22 2009-08-26 ノバルティス アクチエンゲゼルシャフト 移植片の機能発現遅延の処置のための医薬の製造のためのリンパ球ホーミング促進剤の使用
JP4588979B2 (ja) * 2001-04-20 2010-12-01 オプタルモファーマ アクチェンゲゼルシャフト プロドラッグとして使用されうる修飾型シクロスポリン及びその使用
ES2322442T3 (es) * 2001-06-08 2009-06-22 Novartis Ag Tratamiento o profilaxis del rechazo de injertos de celulas productoras de insulina.
GB0117921D0 (en) * 2001-07-23 2001-09-12 Novartis Ag Organic compounds
US7780993B2 (en) * 2001-09-07 2010-08-24 Yeda Research And Development Co. Ltd. Therapeutic transplantation using developing, human or porcine, renal or hepatic, grafts
US20040136972A1 (en) * 2001-09-07 2004-07-15 Yeda Research And Development Co. Ltd. Methods of treating disease by transplantation of developing allogeneic or xenogeneic organs or tissues
GB0125443D0 (en) 2001-10-23 2001-12-12 Novartis Ag Organic Compounds
MXPA04006709A (es) 2002-01-11 2004-10-04 Sankyo Co Derivados de aminoalcohol o derivados de acido fosfonico y composiciones farmaceuticas que los contienen.
GB0217777D0 (en) * 2002-07-31 2002-09-11 Novartis Ag Organic compounds
IL165425A0 (en) * 2004-11-28 2006-01-15 Yeda Res & Dev Methods of treating disease by transplantation of developing allogeneic or xenogeneic organs or tissues
CA2707750A1 (en) 2003-04-08 2004-10-21 Novartis Ag Solid pharmaceutical compositions comprising a s1p receptor agonist and a sugar alcohol
US7524887B2 (en) 2003-06-06 2009-04-28 Sanofi-Aventis Deutschland Gmbh 2-amino-1,3-propanediol compounds for the treatment of acute pain
EP1484057A1 (en) * 2003-06-06 2004-12-08 Aventis Pharma Deutschland GmbH Use of 2-amino-1-3-propanediol derivatives for the manufacture of a medicament for the treatment of various types of pain
US7838562B2 (en) * 2003-06-24 2010-11-23 University Of Connecticut Methods of inhibiting vascular permeability and apoptosis
US7074659B2 (en) * 2003-11-13 2006-07-11 Volterra Semiconductor Corporation Method of fabricating a lateral double-diffused MOSFET (LDMOS) transistor
KR20110136901A (ko) 2004-02-24 2011-12-21 상꾜 가부시키가이샤 아미노 알코올 화합물
PL1773307T3 (pl) * 2004-07-30 2015-03-31 Novartis Ag Preparaty 2-amino-1,3-propanodioli i ich analogów
RU2433117C2 (ru) 2005-12-15 2011-11-10 Мицубиси Танабе Фарма Корпорейшн Аминное соединение и его применение в медицинских целях
AR085749A1 (es) 2011-04-01 2013-10-23 Novartis Ag Formulaciones
RU2496486C1 (ru) 2012-07-11 2013-10-27 Александр Васильевич Иващенко Фармацевтическая композиция с улучшенной сыпучестью, лекарственное средство, способ получения и применение
AU2014224237B2 (en) * 2013-03-05 2017-07-20 Biocon Limited A process for the preparation of 2-amino-1,3-propane diol compounds and salts thereof
US20180250235A1 (en) 2015-09-18 2018-09-06 Sanovel Ilac Sanayi Ve Ticaret A.S. Fingolimod capsule composition
JP2024521882A (ja) * 2021-05-31 2024-06-04 上海雲晟研新生物科技有限公司 フィンゴリモド薬用塩、製造方法、それを含む医薬組成物及び使用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3904679A (en) * 1972-05-23 1975-09-09 Upjohn Co 15-Methyl and 15-ethyl prostaglandin F{HD 2{331 {0 {B analogs
US6136310A (en) * 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
NZ243706A (en) * 1991-07-25 1994-08-26 Idec Pharma Corp Recombinant monkey antibodies, pharmaceutical compositions
US5747034A (en) * 1992-07-09 1998-05-05 Chiron Corporation Methods and materials for the induction of T cell anergy
GB9221220D0 (en) * 1992-10-09 1992-11-25 Sandoz Ag Organic componds
KR0155015B1 (ko) 1992-10-21 1998-12-01 고우야 마사시 2-아미노-1,3-프로판디올 화합물 및 면역 억제제
WO1997024112A1 (en) 1995-12-28 1997-07-10 Yoshitomi Pharmaceutical Industries, Ltd. External preparation
JP2002241272A (ja) * 1996-07-18 2002-08-28 Mitsubishi Pharma Corp 医薬処方組成物
US6476004B1 (en) * 1996-07-18 2002-11-05 Mitsubishi Pharma Corporation Pharmaceutical composition
EP2030614A1 (en) * 1997-02-27 2009-03-04 Novartis AG Pharmaceutical Composition comprising 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol and a lecithin

Also Published As

Publication number Publication date
NO992259D0 (no) 1999-05-10
ID21568A (id) 1999-06-24
SK284806B6 (sk) 2005-11-03
CZ174999A3 (cs) 1999-08-11
HK1022639A1 (en) 2000-08-18
WO1998022100A3 (en) 1998-06-25
CA2270952C (en) 2007-09-18
IL129824A0 (en) 2000-02-29
EP1312359A3 (en) 2004-01-02
CA2270952A1 (en) 1998-05-28
EP0941082A2 (en) 1999-09-15
BR9713105A (pt) 2000-04-11
CN1146411C (zh) 2004-04-21
EP1312359B1 (en) 2007-08-15
JP4004070B2 (ja) 2007-11-07
PT941082E (pt) 2004-12-31
DE69730727T2 (de) 2005-09-22
PL190348B1 (pl) 2005-11-30
NO992259L (no) 1999-05-10
HUP0000343A3 (en) 2001-06-28
WO1998022100A2 (en) 1998-05-28
PT1312359E (pt) 2007-11-09
CN1293876C (zh) 2007-01-10
IL129824A (en) 2003-07-31
ES2289041T3 (es) 2008-02-01
SK65999A3 (en) 1999-12-10
DE69738033D1 (de) 2007-09-27
US20010056124A1 (en) 2001-12-27
PL333463A1 (en) 1999-12-20
DE69738033T2 (de) 2008-04-30
CN1515253A (zh) 2004-07-28
ES2227726T3 (es) 2005-04-01
EP1312359A2 (en) 2003-05-21
US20030069315A1 (en) 2003-04-10
RU2217136C2 (ru) 2003-11-27
EP0941082B1 (en) 2004-09-15
US6486209B2 (en) 2002-11-26
DK1312359T3 (da) 2007-10-08
ATE275947T1 (de) 2004-10-15
US6274629B1 (en) 2001-08-14
HUP0000343A2 (hu) 2000-12-28
AU728420B2 (en) 2001-01-11
DE69730727D1 (de) 2004-10-21
CN1237906A (zh) 1999-12-08
NZ335629A (en) 2001-09-28
ATE369846T1 (de) 2007-09-15
JP2001503780A (ja) 2001-03-21
JP2004256554A (ja) 2004-09-16
SI1312359T1 (sl) 2008-08-31
AU5483198A (en) 1998-06-10

Similar Documents

Publication Publication Date Title
SI1312359T1 (sl) Uporaba 1,3-propandiolnih spojin
ZA9110166B (en) 1,4-benzothiazepine derivatives
DE69505470D1 (de) Pyrrolocarbazol
GR3015322T3 (en) Substituted beta-diketones.
DE69923744D1 (de) 1,3,8-Triazaspiro[4,5] decanon Verbindungen als orl1-receptor Agonisten
ES2188481T3 (es) Derivados de polinalbufina.
ZA917341B (en) Compound,use and preparation
ES2144327T3 (es) Procedimiento para preparar un compuesto de 2-cianobifenilo.
ES2066564T3 (es) Derivados de n-2-clorobencil-2-oxo y n-2-clorobencil-2,2-dioxo-1,2,3-oxatiazolidina, su preparacion y sintesis de derivados de tieno(3,2-c)piridina de estos.
DE69103985D1 (de) N-Alkylthiazolidinderivate.
EP0443474A3 (en) 1-phenoxycarbonyl-2-pyrrolidinone derivatives and nootropic agents

Legal Events

Date Code Title Description
730 Substitution of applicants allowed (sect. 30/1977)